CD43b (clone Bra7G), anti-human

Source:
A BALB/c mouse was immunized with immature pluripotent human leukemia K562 cells.
Fusion partner: SP2/0.



Specifications:
Bra7G reacts with a 95/115 kDa protein on T-cells and thymocytes and a 115/135 kDa molecule on neutrophils and platelets. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma. In addition, expression is altered in Wiskott Aldrich Syndrome. A proportion of AIDS patients have antibodies to CD43. A soluble form called galactoglycoprotein is present in serum. Bra7G was typed at the 5th International Workshop on Human Leucocyte Differentiation antigens.

Species reactivity:
Positive: human.

Applications:
Bra7G can be used in immunohistology, immunofluorescence, flow cytometry and immunoblotting.
Flow cytometry: +
Frozen sections: +
Immunofluorescence: +
Paraffin sections: Trypsin
Western blot: +

Positive control: Paracortex in a tonsil or a reactive lymph node.

References:
- Chorvath et al., Neoplasma39(6): 325-329(1992).
- Turzova M, et. al. Neoplasma, 40(1): 9-13 (1993).
- Schlossman et. al., SF. Leucocyte Typing V: White cell differentiation antigens. Oxford University Press (1995)